Last reviewed · How we verify
Probenecid tablets
At a glance
| Generic name | Probenecid tablets |
|---|---|
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Nausea, vomiting, or GERD
- Headache or loss of appetite
- Diarrhoea
- Flatulence
- Vomiting
- Nasopharyngitis
- Diarrhea
- Gastrointestinal sounds abnormal
- Laceration
- Presyncope
- Palpitations
Key clinical trials
- Pharmacokinetics of Sulopenem Etzadroxil Plus Probenecid in Adolescents (PHASE1)
- Probenecid Administration for Alcohol Craving and Consumption (PHASE2)
- The Re-Prosper HF Study (PHASE2, PHASE3)
- Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid
- A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060 (PHASE1)
- Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters (EARLY_PHASE1)
- A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants (PHASE1)
- A Relative Bioavailability Study With a Novel PanCytoVir™ Oral Suspension (100 mg/ml) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probenecid tablets CI brief — competitive landscape report
- Probenecid tablets updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI